Clinical Trial Search

Primary: Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intraarterial Doses of C21 — 27.8; 17.2; 37.0; 28.5 percentage of change from baseline

Primary: Area Under the Curve for Rewarming of Each Finger After Cold Challenge (AUC) as Measured by Thermography — 19558.43; 20045.96 C*sec — p==0.3801

Primary: Pharmacodynamic Effect — 1.787; 1.911 score on a scale — p=0.1925

Primary: Microvascular AT2R Sensitivity Following Local Control Treatment — 15; 25 percentage of maximal blood flow

Primary: Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle — 1.66; 3.05; 2.45; 1.92 score on a scale

Primary: Renal Plasma Flow — 541; 663 mL/min — p=< 0.0001

Primary: Systemic, Pulmonary and Cerebral Blood Flow at Baseline and After Enalaprilat — 1.4; 1.8; 1.9; 1.9 l/min/m2 — p=0.09

Primary: Wave Reflection Magnitude — 0.38; 0.44; 0.37 dimensionless ratio

Primary: Change in Urinary Sodium Excretion — 74.43; 29.11 MEq/min — p=0.04

Primary: Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg — -24.9; -1.8 Percent…

Primary: Change in Urinary Sodium Excretion — 29.5; 25.1 MEq/min — p=0.8

Primary: Time-weighted Average (TWA) Change From Baseline (0 Hours) to 12 Hours in Heart-Rate-Corrected Augmentation Index (AIx) After A Single Dose of Treatment — -11.1; -0.7…

Primary: Percentage Change From Baseline to End of Treatment for the Difference Between the Post-ischemia and Pre-ischemia Forearm Vascular Resistance (FVR).

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to TEAEs — 3; 3; 2; 4 Participants

Primary: Radial Artery Cross Sectional Area — 3.4; 3.0 mm^2

Primary: Change in Reactive Hyperemic Index by Period (Carvedilol CR + Lisinopril vs. Lisinopril + HCTZ) — -0.26; -0.14 Ratio

Primary: Change in Glomerular Filtration Rate — -5; 1.00 ml/min/1.73 m2 — p=0.26

Primary: Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement) — -13.65; -9.7 mmHg

Primary: Statistical Analysis of Change From Baseline to Day 3 in Myocardial Perfusion Endpoints Compared With Mid Perfusion Reserve Index Using ANCOVA End Points — -0.244…

Primary: Change in Small Artery Elasticity — 2.4; 1.0; 0.4 (ml/mmHg × 100)

Primary: Flow Mediated Vasodilation — 4.8; 4.4 percentage change over baseline

Primary: Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.) — 0.19; 0.22 mg/L — p==0.4891

Primary: Systolic Blood Pressure — 98; 97; 102; 87 mmHg

Primary: Number of Participants With Adverse Events Occurring Over the Trial Period — 37; 5; 6; 12 Participants

Primary: Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Nasal Short Posterior Ciliary Artery — 8.61; 8.02 Centimeters per second (cm/s)

Primary: ACRPP: 24-hour Ambulatory Central Rate-pressure Product (Also Called TTI, CTTI) — 2531; 2824; 2484 mmHg*beats/min — p=0.05

Primary: Standing and Supine Systolic and Diastolic Blood Pressure (BP) — 118.36; 119.47; 68.06; 69.99 mm Hg

Primary: Flow-Mediated Dilation (FMD) — 3.61; 3.66; 4.22; 3.55 % increase from pre-occlusion value

Primary: Forearm Blood Flow — 96; 105 ml/min

Primary: Forearm Blood Flow — 1.72; 2.29; 1.17; 1.63 mL/min/100 mL